CONMED (CNMD) to Release Quarterly Earnings on Wednesday

Posted by Brian Himes on Jul 22nd, 2026

CONMED (NYSE:CNMD – Get Free Report) is expected to be announcing its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect CONMED to announce earnings of $1.10 per share and revenue of $337.5960 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $317.05 million during the quarter, compared to analysts’ expectations of $310.64 million. CONMED had a return on equity of 13.84% and a net margin of 4.00%.The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.95 EPS. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Price Performance

Shares of CONMED stock opened at $41.90 on Wednesday. The company has a current ratio of 2.29, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $1.26 billion, a PE ratio of 23.67, a price-to-earnings-growth ratio of 3.21 and a beta of 0.93. The business’s 50-day moving average price is $36.09 and its 200-day moving average price is $38.37. CONMED has a 12 month low of $31.44 and a 12 month high of $56.63.

Wall Street Analysts Forecast Growth

CNMD has been the topic of a number of recent research reports. BMO Capital Markets assumed coverage on shares of CONMED in a research report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price target on the stock. Wall Street Zen upgraded shares of CONMED from a “hold” rating to a “buy” rating in a report on Monday. Wells Fargo & Company set a $39.00 price objective on shares of CONMED in a research note on Monday, July 13th. Bank of America reaffirmed an “underperform” rating and set a $40.00 target price on shares of CONMED in a report on Monday, June 29th. Finally, Zacks Research cut shares of CONMED from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Five investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $38.80.

View Our Latest Stock Report on CONMED

Hedge Funds Weigh In On CONMED

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its position in CONMED by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,312,804 shares of the company’s stock valued at $53,301,000 after purchasing an additional 16,028 shares during the last quarter. Wasatch Advisors LP purchased a new position in shares of CONMED in the third quarter worth $47,026,000. Deerfield Management Company L.P. grew its holdings in CONMED by 8.6% in the 3rd quarter. Deerfield Management Company L.P. now owns 760,196 shares of the company’s stock worth $35,752,000 after acquiring an additional 59,925 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in CONMED by 2.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 417,541 shares of the company’s stock worth $16,952,000 after acquiring an additional 11,126 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of CONMED in the fourth quarter valued at about $9,029,000.

About CONMED

(Get Free Report)

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.